Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents could be given in combination or in sequence on the basis of previous response...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, Morgan, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043012/
https://www.ncbi.nlm.nih.gov/pubmed/31624047
http://dx.doi.org/10.1016/S2352-3026(19)30167-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043012/
https://www.ncbi.nlm.nih.gov/pubmed/31624047
http://dx.doi.org/10.1016/S2352-3026(19)30167-X

Ejemplares similares